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Abstract
Background: Neovascularization and peritumoral edema are hallmarks of glioblastoma (GBM). Programmed cell
death 10 (PDCD10) plays a pivotal role in regulating apoptosis, neoangiogenesis and vessel permeability and is
implicated in certain tumor signaling pathways. However, little is known about PDCD10 in GBM. We aimed to
investigate the expression pattern of PDCD10 and to identify the association of its expression with some molecular
and clinical parameters in human GBM.
Methods: mRNA and protein expression of PDCD10 were examined respectively by real-time RT-PCR and Western
blotting in GBM (n = 27), astrocytoma grade II (n = 13) and control (n = 11). The protein level of p-Akt and GFAP was
detected by Western blot. Double-imunofluorecent staining was performed to reveal the cellular expression profile
of PDCD10. Brain edema and microvascular density (MVD) were respectively analyzed based on pre-operative MRI
and after laminin immnostaining. MGMT promoter methylation was detected by methylation specific PCR.
Results: mRNA and protein levels of PDCD10 were significantly downregulated in GBM, concomitantly accompanied
by the activation of Akt. PDCD10 immunoreactivity was absent in proliferating tumor cells, endothelial cells
and GFAP-positive cells, but exclusively present in the hypoxic pseudopalisading cells which underwent
apoptosis. Moreover, loss of PDCD10 was associated with a higher MVD and a more severe peritumoral
edema but not with MGMT promoter methylation in GBM.
Conclusion: We report for the first time that PDCD10 expression is downregulated in GBM, which is associated with
the activation of Akt signaling protein. PDCD10 is potentially implicated in tumor proliferation and apoptosis,
hyperangiogenesis and peritumoral edema in GBM.
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Background
Glioblastoma (GBM) is the most aggressive brain tumor
in the central nervous system (CNS) and accounts for
approximately 60-70 % of all gliomas. Patient outcome
following standard therapy comprised of surgery, radio-
therapy, and chemotherapy remains poor. The presence
of microvascular hyperplasia and necrotic foci is unique
feature of GBM, distinctly distinguished from low grade
astrocytoma [1]. Therefore, anti-angiogenic drug regi-
mens are at present increasingly incorporated into com-
bination therapies for GBM [2]. Current anti-angiogenic
approaches mainly include anti-VEGF pathway and anti-
VEGF-independent pathways. These approaches have
clearly improved the response to radiological therapy
and reduced brain edema, but do not significantly influ-
ence overall survival of GBM patients. Thus, to bridge
this gap, the identification of emerging molecular targets
for GBM therapy becomes increasingly important.
Programmed cell death 10 (PDCD10) has originally
been referred to as TFAR15 (TF-1 cell apoptosis related
gene) and is also known as cerebral cavernous malfor-
mation 3 (CCM3). Mutations of PDCD10 predispose to
the development of human familial cerebral cavernous
malformations (CCM), a brain vascular anomaly involving
aberrant angiogenesis and chronic hemorrhage [3, 4].
PDCD10 is evolutionary conserved and is ubiquitously
expressed in nearly all tissues. In the CNS, PDCD10 is
expressed in neuronal, glial and endothelial cells [5, 6].
Biochemically, PDCD10 is an adaptor protein that can
bind to different proteins and/or protein complexes such
as CCM2; each of three germinal center kinases III
(GCKIII) serine/threonine kinases (STK24, STK25 and
MST4); paxillin and VEGFR2 [7]. The crucial role of
PDCD10 in vascularization and in angiogenesis has been
well documented [8–11]. Moreover, much attention has
recently been drawn to the study of the PDCD10 function
in vessel permeability due to the aggressive hemorrhagic
behavior observed in cerebral cavernous malformation pa-
tients harboring a PDCD10 mutation [12] and after loss of
heterozygosity (LOH) for Pdcd10 in mice [8]. Loss of
PDCD10 leads to the disruption of endothelial cell-cell
junctions, to impairment of vascular stability through
hyperactivation of RhoA and to an increase in stress fiber
assembly [13]. In addition to its established endothelial
function, PDCD10 is also essential for the neuron-glial
unit. Vascular pathology has been induced after targeted
deletion of Pdcd10/Ccm3 in murine neuroglia [14] and
PDCD10 has been found to be required for the neuronal
migration [15].
Increasing evidence indicates a pivotal role of PDCD10
in regulating cell survival and death. Both anti-apoptotic
[16–18] and pro-apoptotic functions of PDCD10 [19–22]
have been reported in different type of cells, suggesting a
context-dependent apoptotic function of PDCD10.
Moreover, gene chip analysis indicated the involvement of
PDCD10 in tumor signaling [23] and in resistance to
chemotherapy-triggered apoptosis [24].
The signaling pathways underlying the angiogenesis,
vascular permeability and apoptotic functions of PDCD10
have been intensively studied and reviewed in recent
publications [7, 25]. In our group, we have reported
that silencing PDCD10/CCM3 stimulated endothelial
angiogenesis through activating VEGF signaling and
impairing Dll4-Notch signaling. Indeed, loss of PDCD10
induced apoptosis resistance in endothelial cells after
apoptotic stimuli, accompanied by the activation of p38,
Erk1/2, and Akt signaling proteins [22, 26].
In line with the crucial role of PDCD10 in angiogenesis,
vessel permeability and apoptosis and based on the altered
expression of PDCD10 in various cancers, we assumed
that PDCD10 could be potentially involved in the path-
ology of GBM. To this end, we studied the expression of
PDCD10 at both mRNA and protein levels, and character-
ized the regional and cellular expression profile of this
protein in GBM. The expression of PDCD10 was corre-
lated to the tumor cell survival signaling protein p-Akt, to
microvascular density and peritumour edema in GBM.
Methods
Patient cohort and magnetic resonance imaging
(MRI)-based edema grading
The study comprised 27 primary GBM and 13 astro-
cytoma WHO grade II (Astro II) adult patients, re-
spectively, who underwent surgery from 2009 to 2011
at our department. All experiments were performed
with histopathologically confirmed tumor material
containing the tumor core and the infiltration zone.
The surgical specimens of patients who underwent
anterior temporal lobe resections due to temporal
lobe epilepsy were used as control tissue (n = 11). Pre-
operative MRI was used to grade peritumoral edema
in all patients according to the protocols established
in our previous study [27]. Briefly, grading was per-
formed only if edema was detected in the preopera-
tive image; otherwise the patient was included in the
“grade 0” subgroup. Edema was identified as a peritu-
moral hyperintense signal in T2-weighted MRI. Pa-
tients were categorized as grade 1 if the edematous
area was less than tumor volume, as grade 2 if the
edematous and tumor volumes were equal and as
grade 3 if the edematous area was larger than the
tumor mass. Brain edema grading was performed
prior to determining PDCD10 expression by two
independent investigators. The study was strictly per-
formed according to the Declaration of Helsinki and
approved by the local ethics committee of the University
Hospital of Essen. Informed consent was obtained from
the patients.
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Real-time reverse transcription-PCR (RT2-PCR)
Total RNA and cDNA synthesis were performed as
described in our previous publication [27]. The primers
and the real time-PCR settings were used according to
the established protocol [26]. Relative mRNA expression
(fold of change) was calculated according to the cycle
threshold approach (2-ΔΔCt method) and normalized to
the reference gene GAPDH.
Western blot
Total protein extraction and electrophoresis were done
according to the previous protocol [27]. The following
primary antibodies were used: rabbit anti-PDCD10
(Atlas; 1:400), rabbit anti-GAPDH (14C10) (Cell Signal-
ing; 1:1000), rabbit anti-phospho-Akt (p-Akt, Cell Sig-
naling; 1:600), rabbit anti-RhoA (Santa Cruz Technology,
1:200), rabbit anti-phospho-myosin light chain 2
(Thr18/Ser19) (p-MLC2) (Cell Signaling; 1:1000) and
mouse anti-GFAP (Sigma Aldrich; 1:5000), For semi-
quantification of the blot, integrated optical density
(IOD) of the bands was measured by Image J software.
The relative expression of a target protein was calculated
by the IOD ratio of the target protein to the housekeeping
protein GAPDH, and the data were presented as percent-
age of the control.
Immunostaining
Immunostaining of laminin was performed as described
previously [27]. For immunofluorescent staining of
PDCD10, sections were incubated with rabbit anti-
PDCD10 (Atlas, 1:65) at 4 °C overnight and then
incubated with biotinylated goat anti-rabbit IgG
(Dako, 1:400) at 37 °C for 1 h followed by the sub-
strate reaction with FITC-labelled avidin (Dako,
1:400) at room temperature for 1 h. For double-
immunofluorecent staining, the following antibody
mixtures were applied to the sections: rabbit anti-
PDCD10 (Atlas, 1:65) and mouse anti-GFAP (Sigma,
1:200); rabbit anti-PDCD10 and mouse anti-CD31
(Dako, 1:20); rabbit anti-PDCD10 and mouse anti-
CD68 (Dako, 1:100); rabbit anti-PDCD10 and mouse
anti-PCNA (Dako, 1:200); mouse anti-PDCD10 (Santa
Cruze, 1:50) and rabbit anti-caspase 3 (active form)
(Cell signaling, 1:400). After incubation overnight,
the sections were incubated with the mixture of bio-
tinylated goat anti-rabbit IgG (1:400) and Texas red
anti-mouse IgG (H + L) (Vector Laboratories, 1:200)
followed by the substrate reaction with FITC-labelled
avidin. Counterstaining was performed with Hoechst-
33258. The sections were finally analyzed by using a
fluorescence microscope with ApoTome System
(Zeiss, Axio Imager M2).
Evaluation of microvascular density (MVD) and
O6-methylguanine-methyltransferase (MGMT) promoter
methylation
MVD evaluation and methylation specific PCR (MSP)
analysis of MGMT promoter methylation were per-
formed using the protocols established in our previous
study [27].
Statistical analysis
All statistical analyses were performed using the Graph-
Pad-Prism Software Version 4. Student’s t test with
Welch’s correction was performed for data analysis. P <
0.05 was considered as significant difference between
groups.
Results
Downregulation of PDCD10 expression in GBM
RT2-PCR revealed a significant downregulation of
PDCD10 in GBM compared to the control (p < 0.01)
and to the Astro II group (p < 0.05). Of note, 23 out of
27 GBM samples (85.2 %) exhibited individual mRNA
levels below the mean value of “fold of change”, indicat-
ing a dominant downregulation of this gene in the ma-
jority of investigated GBM cases (Fig. 1a). Western blot
confirmed an approximately 60 % reduced expression of
PDCD10 in GBM in comparison to the control group
(Fig. 1b) (p < 0.01). The expression of mRNA and protein
of PDCD10 in Astro II was slightly decreased but this
was not statistically different from that in controls. Inter-
estingly, the level of p-Akt, a crucial signaling protein
for tumor cell survival and proliferation, was inversely
associated with PDCD10 expression in Astro II (p <
0.05) and in GBM (p < 0.001) (Fig. 1c), whereas GFAP, a
marker of astrocytoma tumors and expressed in differ-
entiated astrocytes, was detected at varying levels in in-
dividual tumor tissues and did not show a significant
difference among three groups (Fig. 1d and e).
PDCD10 immunoreactivity was absent in the majority of
endothelial and tumor cells but was exclusively detected
in pseudopalisades of GBM
Microscopically, necrosis and microvascular proliferation
are typical morphologic features of GBM which distin-
guish this tumor from low grade astrocytoma. As shown
in Fig. 2a-c, tumor cells in GBM were often accumulated
and arranged in a perpendicular (pseudopalisading) fash-
ion (arrows) around necrotic areas (asterisks). The nec-
rotic center was either built by a clear zone (less sever
necrosis) (asterisk in Fig. 2b) or by severely necrotic cells
(asterisk in Fig. 2c). Microvascular hyperplasia as shown
by laminin staining (violet-colored vessels in Fig. 2b and c)
was often found in adjacent pseudopalisading area where
tumor cell growth was sustained.
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Next, we focused on identifying the regional and cellular
expression profile of PDCD10 in GBM by immunofluore-
cent staining of PDCD10 on GBM sections. No immune-
signal was detected in negative staining control in which
non-specific Ig, instead of primary antibody, was applied
to the section followed by count-staining with Hoechst
33258 (Fig. 2f). In contrast, intensive immunoreactivity of
PDCD10 was observed on a control brain section (Fig. 2g).
In GBM sections, PDCD10 immunoreactivity was absent
in the central clear zone (asterisk in Fig. 2d) and in the
tumor cell dense infiltration area. Surprisingly, PDCD10
was exclusively detected in the peripheral cellular pseudo-
palisades as shown in Fig. 2d. Figure 2e is the high magni-
fication view of the dash-lined area of Fig 2d. This distinct
PDCD10 expression manner was also observed in the
pseudopalisades with a more pronounced necrotic center
(Fig. 2h) and in throughout GBM sections. Double
staining of PDCD10 and GFAP revealed no overlapped
expression of PDCD10 and GFAP in pseudopalisading
cells (Fig. 2h) and in the infiltration zone (Fig. 2i),
suggesting that PDCD10 expression is independent of
astrocytic differentiation. It is noteworthy that the nu-
merous microvessel-like structures in the infiltration
zone exhibiting PDCD10-negative staining (arrows in
Fig. 2i). Double staining of PDCD10 and the endothe-
lial marker CD31 confirmed this observation (Fig. 2k),
and furthermore, these PDCD10-negative microvessels
showed proliferation activity as evidenced by the
double staining of PDCD10 (green) and PCNA (red)
(Fig. 2l). As shown in a high magnification view
(inserted white box in Fig. 2l) of dash-lined area in
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Fig. 1 Downregulation of PDCD10 was correlated to the activation of Akt in GBM. a Downregulation of PDCD10 mRNA. Real time RT-PCR
demonstrated a downregulation of PDCD10 in a malignancy dependent manner in glioma. b-d Downregulation of PDCD10 protein expression was
inversely correlated to the level of p-Akt in GBM. Semi-quantification of the blots confirmed a significant downregulation of PDCD10 protein level in
GBM (b), which was inversely correlated to an activation of Akt (c). The level of GFAP was not significantly different among the control (c), astrocytoma
grade II (Astro II) and GBM (d) group. e A representative blot showed the expression of PDCD10, phosphor-Akt (p-Akt), and GFAP in control (c), Astro II
and GBM. * p < 0.05, ** p < 0.01 and *** p < 0.001, compared to c
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in the nucleus of a PDCD10-negative endothelial cell.
Interestingly, the thrombosed microvessels in/nearby
the necrotic area were PCNA negative (arrow in
Fig. 2m) but often accompanied by the induction of
PDCD10 expression in the area surrounding the
thrombosed vessel (Fig. 2m), suggesting a hypoxia-
induced PDCD10 expression. Some of these PDCD10-
expressing cells were positively labelled with CD68
(arrows in Fig. 2j), indicating PDCD10 expression in
macrophage.
x5 x5x10
Fig. 2 Characterization of the regional and cellular localization of PDCD10 immunoreactivity in GBM. a Histopathological feature of GBM. H&E
staining outlined multiple pseudopalisades. A typical pseudopalisade is composed of peripheral cellular pseudopalisading (arrows) around a
necrotic center (asterisks). b and c Laminin staining. Microvascular hyperplasia (violet-colored structure) was found predominantly close to the
pseudopalisading. Peripheral cellular pseudopalisading (arrows) was highlighted by the counterstaining. d-g Immunostaining of PDCD10.
PDCD10 immunoreactivity was absent in the necrotic center (asterisk in d). High magnification view of the white box in d indicated that
PDCD10 immunoreactivity was not detected in infiltrating tumor cells distant from necrotic area but was exclusively present in peripheral
cellular pseudopalisading (e). Negative staining control omitting the primary antibody did not show any detectable signal (f), whereas the
staining on a control brain section detected intensive immunoreactivity of PDCD10 (g). h-m Double staining of PDCD10 (green) with
different cellular markers (red). PDCD10-positive cells in peripheral cellular pseudopalisading were not co-localized with GFAP (low magnification view
in h and high magnification view in the inserted box). In the necrosis-distant area (infiltration area), tumor cells were positively labelled with
GFAP but were negative to PDCD10-staining (i); meanwhile numerous microvessel-like structures in this infiltration area did not show PDCD10
immunoreactivity (arrows in i). Absence of PDCD10 in endothelial cells of the microvessels was confirmed by the double staining of PDCD10
and CD31 (arrows in k). These PDCD10-negative vessels exhibited proliferating activity as evidenced by the staining with PCNA (arrow
and inserted box in l). In contrast, the thrombosed vessel (arrow in m) did not label with PCNA rather induced PDCD10 expression in
surrounding tumor cells (m). Some of PDCD10 positive cells were co-labelled with macrophage marker CD68 (arrows in j)
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PDCD10 expression was inversely correlated to the
proliferation of tumor cells and vascular endothelial cells
but was positively associated with apoptosis
To further investigate the association of PDCD10 ex-
pression and the status of tumor cells, i.e., proliferation
or apoptosis, we performed double staining of PDCD10/
PCNA and PDCD10/caspase 3 (active form). In pseudo-
palisades, PDCD10-positive cells (green) did not co-stain
with PCNA (Fig. 3a) but were exclusively co-labelled
with active caspase 3 as revealed in low (Fig. 3c) and
high (Fig. 3d) magnification views of the GBM section.
The co-expression of PDCD10 and active caspase 3 was
also detected in the pseudopalisades with a severely nec-
rotic center (Fig. 3e and f). In contrast, nearly all tumor
cells and microvessel endothelial cells (arrows in Fig. 3b)
in the infiltrating zone were absent of PDCD10
immuno-signal (green) but showed strong PCNA
immunoreactivity (red) (Fig. 3b) and appeared negative
for caspase 3 staining (Fig. 3c and e).
The association of PDCD10 expression with microvascular
density (MVD)
MVD is a parameter associated with angiogenesis in
solid tumors. When GBM patients were subgrouped
based on the PDCD10 mRNA level, MVD was 37 vessel/
mm2 and 78 vessel/mm2 in the subgroups of “fold of
change (foc) > 0.5” and “foc < 0.5”, respectively (p < 0.01)
(Fig. 4a). Similarly, MVD was significantly higher in the
GBM subgroup expressing lower PDCD10 protein
(<50 % of the control) than that with higher PDCD10
expression (> 50 % of the control) (p < 0.01) (Fig. 4b).
These results indicate an inverse correlation of PDCD10





Fig. 3 The association of PDCD10 expression with tumor cell proliferation and with caspase 3 activation. a and b Double staining of PDCD10 and
PCNA in GBM. PDCD10-positive cells (green) exclusively detected in pseudopalisading did not co-stain with PCNA (red) (a), whereas nearly all tumor
cells the tumor microvessels (arrows in b) in the infiltration area appeared negative to PDCD10 staining but showed strong PCNA immunoreactivity
(red), indicating an inverse correlation of PDCD10 expression and proliferation status of tumor cells and microvessels (b). c-f Double staining of PDCD10
and active caspase 3. Co-localization of the immunoreactivity of PDCD10 (green) and active caspase 3 (Cas3) (red) was exclusively detected in peripheral
cellular pseudopalisadings, suggesting that an association of PDCD10 expression and apoptosis. Of note, the selective expression of PDCD10 in the
pseudopalisading area was independent of whether pseudopalisading formed around a slight (c) or a severe necrotic zone (e). d and f, respectively,
show the high magnification view of the white boxes in c and d. Asterisk in a and c-f indicates the necrotic center
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Association of PDCD10 expression with methylation
status of MGMT and with peritumoral edema
Hypermethylation of the MGMT gene has been shown
to be associated with improved outcome in glioblastoma
(GBM) and may be a predictive marker of sensitivity to
chemotherapy with alkylating agents and to radiation
therapy in GBM. Thus, the promotor methylation status
of MGMT is routinely examined in GBM patients in our
hospital and most other tertiary care centers. Among 27
GBM, 10 of 27 GBM (37 %) were positive for the pro-
moter methylation of MGMT. The association analysis
revealed that the mean of “fold of change” of PDCD10
mRNA was 0.30 ± 0.08 and 0.42 ± 0.07 in MGMT-meth-
ylated GBM and in MGMT-non methylated cases, re-
spectively (p > 0.05), suggesting that MGMT methylation
status is not associated with PDCD10 expression level in
GBM.
PDCD10 has been shown to affect vessel permeability
through RhoA signaling [13, 14, 28, 29]. We thus evalu-
ated peritumoral edema and analyzed the association of
the grade of edema with PDCD10 protein expression
and with p-MLC2, a downstream kinase of RhoA.
Figure 5a is representative of different edema grades
in GBMs. Interestingly, the PDCD10 protein expres-
sion decreased in an edema grade-dependent manner
in GBM (Fig. 5b). The patients with a severe peritu-
moral edema (grade III) expressed a significant lower
protein level of PDCD10 in comparison to the cases
without edema (grade 0) (p < 0.001) (Fig. 5b). The
expression of p-MLC2 seems to be correlated to the
level of total RhoA in GBM, but both p-MLC2 and
RhoA levels appeared varying in individual GBM
tissues (Fig. 5d). Semi-quantification of p-MLC2 and
RhoA blots did not reveal statistically significant
difference between GBM and the control group
(Fig. 5c).
Discussion
In contrast to the well-established function of PDCD10
in vasculogenesis, neo-angiogenesis, vessel remodeling
and vessel permeability, only limited information is
available on PDCD10 in malignant tumors despite its
original description as an apoptosis related gene [30].
Here we report for the first time that PDCD10 expres-
sion at both mRNA and protein levels decreased in a
malignancy-dependent manner in glioma. A significant
downregulation of PDCD10 was found in GBM, the
most aggressive glioma, concomitantly accompanied by
the activation of Akt. Loss of PDCD10 immunoreactivity
was identified in proliferating tumor and vascular endo-
thelial cells as well as in tumor cells. Interestingly,
PDCD10 immunoreactivity was selectively detected in
pseudopalisading cells which were positively labelled
with active caspase 3, suggesting a possible direct role of
PDCD10 in regulating apoptosis in this hypoxia region.
Moreover, downregulation of PDCD10 was associated
with a higher microvascular density, and with more
severe peritumoral edema in GBM. These results indi-
cate that PDCD10 expression is deregulated in GBM,
which is potentially involved in the regulation of tumor
cell proliferation and apoptosis and in the pathology of
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Fig. 4 Inverse association of the expression of PDCD10 with
microvascular density (MVD) in GBM. a The association of PDCD10
mRNA expression and MVD. When GBM was subgrouped based on
the mRNA level of PDCD10 (“fold of change” (foc) < 0.5, n = 20; or > 0.5,
n = 7), a significantly higher MVD was observed in the subgroup
expressing lower PDCD10 (foc < 0.5) in GBM. b The association of
PDCD10 protein expression and MVD. When GBM was subgrouped
based on the protein level of PDCD10 < 50 % of control (n = 22); or >
50 % of control (n = 5), a significantly higher MVD was observed in the
subgroup expressing PDCD10 < 50 % of control. ** p < 0.01, compared
to the group expressing lower mRNA (a) or protein (b) of PDCD10
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Distinct PDCD10 expression in GBM: Lack of PDCD10
expression in microvessels and in infiltrating tumor cells
but selective expression in pseudopalisading cells
PDCD10 is highly conserved across species and is
ubiquitously expressed in all normal tissues including
brain tissue. Aberrant expression of PDCD10 gene tran-
scription has previously been detected in various types
of human cancers [31]. Indeed, an altered expression of
PDCD10 was found in response to different chemother-
apies, giving rise to the hypothesis that PDCD10 is
involved in chemoresistance in certain cancers [24, 32].
However, it is unclear whether the expression of this
apoptosis related gene/protein is altered in GBM. Here,
we reported for the first time the downregulation of
PDCD10 mRNA and protein in a malignancy-dependent
manner in gliomas, accompanied by a significant activa-
tion of Akt, an important signal protein regulating cell
survival and angiogenesis (Fig. 1). To date, only few
reports have regarded the regulation mechanism of
PDCD10 expression. Chen et al., identified c-Myc as an
important coordinator for the transcription of PDCD10
[33]. Transcription of PDCD10 was driven by the bind-
ing of c-Myc to a non-canonical E-Box element in the
promoter of PDCD10; and moreover, this binding can be
interfered by the methylation at a specific nucleotide in
this E-Box thereby suppressing the transcription of
PDCD10. Whether this mechanism accounts for the
downregulation of PDCD10 detected in GBM needs to
be further studied in the future.
The histopathologic features that distinguish GBM
from lower grade astrocytoma include the presence of
pseudopalisading necrosis and microvascular hyperplasia
(Fig. 2a-c). The former consists of necrosis foci, usually
surrounding cellular pseudopalisades; and the latter is a
form of neo-angiogenesis. These two characteristics are
thought to contribute mechanically to the transition of
lower grade of astrocytoma to GBM and are the most
powerful predictors of poor prognosis in GBM [34]. This
unique pathological feature of GBM seems to be the
consequence of hypoxia. Brat DJ et al., found that more
than 50 % of pseudopalisades contained degenerated or
thrombosed vascular lumina [34], which leads to
regional hypoxia and the outward migration of glioma
cells away from the hypoxia area. The majority pseudo-
palisading cells undergo apoptosis but not proliferation
[35]. The present study identified the absence of
PDCD10 expression in tumor cells and endothelial cells
in the infiltration area and in the necrotic center of
GBM but an exclusive expression of PDCD10 in some
pseudopalisading cells, indicating a distinct regional
expression manner of PDCD10 (Fig. 2d and e; h and i).
We assume that the expression of PDCD10 in pseudopa-
lisading cells results from hypoxia because upregulation
of PDCD10 was observed in response to oxidative stress
































Fig. 5 The association of PDCD10 expression and the grade of brain
edema in GBM. a Grading peritumoral edema in GBM. The grade of
peritumoral edema in GBM was evaluated based on magnetic
resonance imaging (MRI). b The association of PDCD10 protein
expression and the grade of edema. The expression of PDCD10 was
inversely correlated to the grade of peritumoral edema. *** p < 0.001,
compared to edema grade 0. c and d The expression of total RhoA
and phosphor-MLC2 (p-MLC2) in GBM. The expression of RhoA and
phosphor-MLC2 (p-MLC2) appeared to be increased in GBM compared
to the control (c) but did not show statistically significant difference (c).
Thus, downregulation of PDCD10 did not seem to be correlated to the
activation of RhoA signaling. The representative blots are shown in d.
** p < 0.01, compared with control (c)
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[21] and to hypoxia stimuli (own unpublished data). This
hypothesis could be also supported by the detection of
PDCD10 immunoreactivity in the area nearby the
thrombosed and non-proliferating vessel (Fig. 2m).
The association of PDCD10 expression with cell
proliferation and apoptosis
By means of double staining, we further characterized
the cellular location of PDCD10 immunoreactivity and
the potential association of its expression with cell pro-
liferation and apoptosis. Lack of PDCD10 in CD31- and
PCNA-positively vascular endothelial cells (arrows in
Fig. 2k and l and in Fig. 3b) suggests that loss of
PDCD10 is associated with endothelial proliferation.
This observation is in agreement with our previously
finding that silencing PDCD10 in endothelial cells stimu-
lated endothelial angiogenesis including proliferation, mi-
gration, sprouting and angiogenesis [22, 26]. Furthermore,
we demonstrated that loss of PDCD10 immunoreactivity
in tumor cells in the infiltration area was associated with
tumor cell proliferation (Fig. 3b), whereas PDCD10-
expression cells in pseudopalisades were co-labelled with
active caspase 3 (Fig. 3c-f). These results indicate an
inverse association of PDCD10 expression with the tumor
cell proliferation but a positive correlation with apoptosis,
suggesting an implication of PDCD10 in determining the
fate of tumor cells in GBM.
Downregulation of PDCD10 was inversely associated with
the microvascular density and with the grade of
peritumoral edema
Massive neo-angiogenesis and peritumoral edema are
hallmarks of GBM. Growth of malignant gliomas is at
least partially dependent on neo-angiogenesis, whereas
vasogenic brain edema is a direct consequence of the
vascular abnormalities in GBM and is a significant cause
of morbidity of GBM [36]. In spite of its well-established
pro-angiogenic function [22, 26] and vessel hyper-
permeability [13, 14, 28, 29] induced by PDCD10-
deficiency, the present study reported for the first time
that the downregulation of PDCD10 is inversely associ-
ated with MVD (Fig. 4) and with a higher grade of brain
edema in GBM (Fig. 5). It has been previously shown
that loss of PDCD10 leads to the disruption of endothe-
lial cell-cell junctions and to impair vascular stability
through hyperactivation of RhoA and an increase in
stress fiber assembly [13]. However, Chan et al. showed
that silence of PDCD10 in endothelial cells did not affect
RhoA signaling but resulted in lumen formation defect
[8]. In the present study, we did not observe a significant
increase in p-MLC2 expression in GBM, suggesting no
correlation between PDCD10 downregulation and acti-
vation of RhoA signaling. Therefore, it is an issue of
future interest to study the underlying signaling pathway
of PDCD10 mediating peritumoral edema in GBM.
Heterozygous loss-of-function mutations in PDCD10/
CCM3 may predispose to familial CCM [3, 4, 12]. The
underlying mechanism of PDCD10 in the pathogenesis
of CCM has been extensively studied [7, 25, 37]. Inter-
estingly, the clinical relevance of CCM and brain tumors
has been observed by independent groups and reviewed
by Mian MK et al [38], although the co-incidence of
CCM and brain tumors is rare. Several studies have
shown that a low grade astrocytoma [39], or GBM [38,
40] or an intracranial ependymoma [41] occurred at the
site of a pre-exiting CCM lesion, and importantly these
patients often had a CCM family history. A recent study
has highlighted the possible association of CCM with
meningiomas in a large cohort of familial CCM harboring
PDCD10 mutations [12]. However, a causal relationship of
CCM and other brain tumor remains unproven.
Nevertheless, these data suggest a potential genetic
mechanism implicated in the collision of CCM and
intracranial neoplasms.
Conclusion
PDCD10 is a remarkably conserved and ubiquitously
expressed protein. Significant downregulation of this
protein in GBM implies its possible involvement in the
pathology of GBM. The association of PDCD10 down-
regulation with the activation of Akt, with hyper-
angiogenesis and with higher a grade of peritumoral
edema suggests a potential function of PDCD10 in
tumor cell survival, angiogenesis and in regulating vessel
integrity. The absence of PDCD10 immunoreactivity in
proliferating tumor and its concomitant co-localization
with apoptotic marker in pseudopalisade tumor cells
may suggest the involvement of PDCD10 in the progres-
sion of GBM. Further investigation is required to
uncover the direct role and the underlying signaling of
PDCD10 deficiency in GBM, which will extend our
understanding on the function of PDCD10 in this tumor.
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